Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 187

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 187
---
 Share will, by virtue of the merger, be exchanged for and converted into the right to receive a newly issued, fully paid -inNLS Common Shares, based on an Exchange Ratio as set forth in the Merger Agreement. For the purpose of making available the required number of Merger Compensation Shares to serve as merger consideration for the Kadimastem shareholders, the Company has agreed to create the necessary Merger Compensation Shares by way of an ordinary capital increase, excluding the subscription rights of existing shareholders of the Company. At the extraordinary shareholders’ meeting, shareholders will be asked to approve the ordinary capital increase to create and issue the Merger Compensation Shares in accordance with the Merger Agreement. The initial Exchange Ratio is estimated to result in Kadimastem shareholders holding approximately 85% of the issued and outstanding Company Common Shares, subject to certain adjustments as of the Closing, including as a result of estimated closing cash of NLS and Kadimastem and estimated closing indebtedness of NLS. Based on the cash balance of NLS as of February27, 2025, the parties currently estimate the fully diluted share split at the Closing will be 80% to Kadimastem shareholders and 20% to NLS shareholders. The number of NLS Common Shares to be approved by the NLS shareholders will therefore include the necessary number of shares to achieve the 80/20 ratio, along with a buffer of approximately 20%. The terms of, reasons for, and other aspects of the issuance of the Company’s ordinary shares as part of the Merger are described in detail in other sections in this prospectus/proxy statement. Please also see “ Preliminary Proxy Statement, Subject To Completion — Notice Of Extraordinary Meeting Of Shareholders To Be Held On , [2025] — 2. Ordinary Share Capital Increase with Contribution of the Kadimastem Shares to Implement the Merger” of this proxy statement/prospectus. To approve this Proposal2, a resolution passed by a Supermajority Vote is required. You may vote “FOR,” “AGAINST” or “ABSTAIN” on Proposal 2. A failure to vote, an abstention or a broker non -vote, if any, will have the same effect as a vote “AGAINST” Proposal 2. THE NLS BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE
“FOR” PROPOSAL 2 79 Approval of ORDINARY SHARE CAPITAL INCREASE BY ISSUING PREFERRED SHARES (PROPOSAL